Loading...
•
Sep 30
Axsome Q3 2025 Earnings Report
Axsome reported a net loss and strong revenue growth driven by AUVELITY and SUNOSI in Q3 2025.
Key Takeaways
Axsome Therapeutics delivered solid revenue growth in Q3 2025, primarily fueled by its leading CNS products AUVELITY and SUNOSI. Despite a reported net loss, the company saw sequential improvements in revenue and reduced losses year-over-year.
Total revenue rose to $171.0 million, a 63% YoY increase.
AUVELITY revenue reached $136.1 million with strong prescription growth.
SYMBRAVO recorded $2.1 million in its first full quarter post-launch.
Net loss narrowed to $47.2 million from $64.6 million YoY.
Axsome
Axsome
Axsome Revenue by Segment
Axsome Revenue by Geographic Location
Revenue by Segment
AUVELITY Revenue
CapyFin.comSUNOSI Revenue
CapyFin.comSYMBRAVO Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Axsome expects its current cash to fund operations into cash flow positivity under its present operating plan.
Positive Outlook
- AUVELITY prescriptions up 46% YoY and 9% QoQ.
- Coverage with all three largest GPOs now secured for AUVELITY.
- SUNOSI prescriptions increased 12% YoY and 5% QoQ.
- Strong cash position of $325.3 million.
- sNDA for AXS-05 in Alzheimer’s agitation submitted to FDA.
Challenges Ahead
- Continued net loss of $47.2 million in Q3.
- High SG&A costs primarily from commercialization efforts.
- No reported free cash flow data.
- Revenue still insufficient to reach profitability.
- Non-cash charges of $13.2 million impacted GAAP results.